Status:
COMPLETED
Observational Study on Efficacy and Safety of Liraglutide in Subjects With Type 2 Diabetes
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18+ years
Brief Summary
This observational study is conducted in Europe. The aim of this non-interventional (observational) study is to evaluate the efficacy of liraglutide (Victoza®) and to assess the conditions of use of V...
Eligibility Criteria
Inclusion
- Patients diagnosed with type 2 diabetes
- Patients having recently started (for less than one week) or starting liraglutide (Victoza®) treatment
Exclusion
- Hypersensitivity (allergy) to liraglutide or to any of the excipients
- Patient is participating in a clinical trial at the inclusion
- Type 1 diabetes
Key Trial Info
Start Date :
September 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2013
Estimated Enrollment :
3152 Patients enrolled
Trial Details
Trial ID
NCT01226966
Start Date
September 1 2010
End Date
November 1 2013
Last Update
February 13 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Paris La Défense Cedex, France, 92932